• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development and application of novel w/o/w emulsion for the chemoembolization therapy of hepatocellular carcinoma

Research Project

Project/Area Number 07672320
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Physical pharmacy
Research InstitutionGifu Pharmaceutical University

Principal Investigator

HINO Tomoaki  Gifu Pharmaceutical University, Faculty of Pharmaceutical Sciences, Assistant Professor, 薬学部, 助手 (90208778)

Co-Investigator(Kenkyū-buntansha) KAWASHIMA Yoshiaki  Gifu Pharmaceutical University, Faculty of Pharmaceutical Sciences, Associate Pr, 薬学部, 教授 (30082978)
TAKEUCHI Hirofumi  Gifu Pharmaceutical University, Faculty of Pharmaceutical Sciences, Associate Pr, 薬学部, 助教授 (50171616)
Project Period (FY) 1995 – 1996
Project Status Completed (Fiscal Year 1996)
Budget Amount *help
¥300,000 (Direct Cost: ¥300,000)
Fiscal Year 1996: ¥300,000 (Direct Cost: ¥300,000)
Keywordsw / o / w emulsion / transcatheter arterial ambolization therapy / epirubicin hydrochloride / lipiodol / acute toxicity / hemolysis / Wエマルジョン / 化学塞栓療法 / 塩酸エピルビシン / 肺水腫
Research Abstract

W/o/w emulsion (WOWE) encapsulating water-soluble anticancer agent (epirubicin hydrochloride, EPI) was prepared by two-step amulsification method. Aqueous and oil phases used were nonionic (iohexol) and oily (lipiodol) contract media, respectively. The agents added in inner and outer aqueous phases were polyoxyethylene hydrated caster oil 60 and gelatin, respectively.
The WOWE was stable emulsion which could encapsulate large amount of EPI and the viscosity was small. The hemolysis percentage was less than that of the o/w emulsion (OWE) used for transcatheter chemoembolization therapy (TAE) conventionally.
The acute toxicities of WOWE and OWE were investigated. The emulsions with and without EPI were administered to the tail vein of rats. The rats administered OWE (*1.5 ml/kg) were deceased within 2 days by pulmonary edema. The rats administered WOWE (*2.0 ml/kg) encapsulating EPI were deceased 7-9 days after administration by the toxicity of EPI.Bleeding and ulcer in the stomach and size reduction of thymus gland were observed in these deceased rats. These pathological damage in the stomach and thymus gland were observed in the rats administered less amounts of OWE than WOWE.This result suggests that the encapsulation of EPI in the WOWE droplets reduced the acute toxicity of EPI.
Therefore, the WOWE newly prepared by us was safer than OWE and desirable formulation for TAE.The effectiveness of WOWE is investigated now and the possible clinical application of WOWE is under investigation.

Report

(3 results)
  • 1996 Annual Research Report   Final Research Report Summary
  • 1995 Annual Research Report
  • Research Products

    (4 results)

All Other

All Publications (4 results)

  • [Publications] 日野知証他: "肝細胞癌の塞栓療法のための塩酸エピルビジン封入W/O/W型エマルションのラットに対する急性毒性の評価" Drug Delivery System. (印刷中). (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1996 Final Research Report Summary
  • [Publications] T.Hino et al.: "Evaluation of acute toxicity of epirubicin hydrochloride-encapsulating w/o/w emulsion administered to rat for the transcatheter embolization therapy for hepatocellular carcinoma" Drug Delivery System. (in print). (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1996 Final Research Report Summary
  • [Publications] 日野 知証 他: "肝細胞癌の塞栓療法のための塩酸エピルビシン封入W/O/Wエマルジョンのラットに対する急性毒性の評価" Drug Delivery System. (印刷中). (1997)

    • Related Report
      1996 Annual Research Report
  • [Publications] 日野 知証: "肝細胞癌の塞栓療法のための塩酸エピルビシン封入W/O/Wリピオドールエマルジョンの設計" Drug Delivery System. 10. 115-119 (1995)

    • Related Report
      1995 Annual Research Report

URL: 

Published: 1996-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi